Robert Ragusa Sells 980 Shares of GRAIL (NASDAQ:GRAL) Stock

GRAIL, Inc. (NASDAQ:GRAL) CEO Robert Ragusa sold 980 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $53.01, for a total transaction of $51,949.80. Following the sale, the chief executive officer owned 649,545 shares of the company’s stock, valued at $34,432,380.45. This represents a 0.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

GRAIL Price Performance

NASDAQ GRAL opened at $48.67 on Wednesday. The firm’s fifty day moving average price is $87.41 and its 200 day moving average price is $78.10. GRAIL, Inc. has a 12 month low of $20.44 and a 12 month high of $118.84. The company has a market capitalization of $1.90 billion, a price-to-earnings ratio of -4.35 and a beta of 5.18.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($2.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.33) by $0.89. The company had revenue of $43.60 million for the quarter, compared to analyst estimates of $43.33 million. GRAIL had a negative return on equity of 17.58% and a negative net margin of 277.46%. As a group, sell-side analysts forecast that GRAIL, Inc. will post -15.15 earnings per share for the current year.

Key GRAIL News

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Institutions adding stakes: Several large funds materially increased positions in Q4 (Farallon, Morgan Stanley, State Street, Baker Bros.), signaling confidence from sophisticated investors and providing a steady demand base. MarketBeat institutional ownership summary
• Positive Sentiment: Recent quarterly results beat EPS estimates (reported ($2.44) vs consensus ($3.33)) and revenue was roughly in line, which supports the case that core business traction (Galleri test adoption) is progressing. (Market reaction is mixed given continued multi-year losses.) Earnings & analyst summary
• Neutral Sentiment: Mixed analyst activity: Some firms trimmed price targets (Morgan Stanley cut to $60, Canaccord lowered targets), while others remain bullish (Guggenheim raised its target earlier). Overall consensus remains around a “Hold” with divergent price targets, adding to uncertainty on near-term direction. Analyst notes
• Negative Sentiment: Short interest jumped in February to ~6.3M shares (16.2% of float), up ~15% from mid‑February; days-to-cover ~1.9. A higher short percent increases downward pressure and volatility, especially given GRAL’s high beta. (Elevated shorting can amplify declines while also enabling short‑squeeze risk.)
• Negative Sentiment: Insider selling by top executives: CEO Robert Ragusa, President Joshua Ofman and CFO Aaron Freidin reported multiple sales in early March (CEO sale filings: Read More.; President filings: Read More.; CFO filings: Read More.). While sizes are modest vs. their holdings, clustered executive sales can spook investors and weigh on sentiment. InsiderTrades article

Institutional Investors Weigh In On GRAIL

A number of hedge funds have recently added to or reduced their stakes in GRAL. N.E.W. Advisory Services LLC acquired a new position in GRAIL during the 4th quarter worth approximately $26,000. Comerica Bank raised its position in GRAIL by 59.2% in the third quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after acquiring an additional 173 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in GRAIL in the fourth quarter valued at $28,000. Elyxium Wealth LLC purchased a new stake in shares of GRAIL during the 4th quarter worth $31,000. Finally, Intesa Sanpaolo S.p.A. acquired a new position in shares of GRAIL during the 4th quarter worth $44,000.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on GRAL shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, January 22nd. Morgan Stanley reduced their price objective on GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 24th. Guggenheim increased their price objective on GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Canaccord Genuity Group cut their price target on GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Finally, TD Cowen initiated coverage on GRAIL in a research note on Thursday, February 19th. They set a “hold” rating and a $114.00 price target for the company. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $90.17.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.